Dr. Reddy’s Laboratories

Dr. Reddy's reported robust financial results for Q3 FY25, with revenue increasing by 14% YoY to ₹8,531 crore ($1.03B). The company continues to focus on expanding its biosimilar portfolio through strategic collaborations, as evidenced by the recent FDA acceptance of their Biologic License Application for AVT03, a proposed biosimilar to Prolia and Xgeva. The company's emphasis on complex chemistry and biology capabilities supports its long-term growth strategy.